Quanterix Stock Price, News & Analysis

Quanterix Corporation (NASDAQ:QTRX) announced that its CEO, Kevin Hrusovsky, will present at the Cowen 41st Annual Health Care Conference on March 3 at 11:00 a.m. EST. A public webcast will be available at this link and will be accessible for 90 days post-event. Additionally, Hrusovsky will feature on the Health Care Rounds Podcast on February 26, discussing precision health. This episode airs at noon EST and will be available on major podcast platforms. Quanterix focuses on advancing precision health through digital biomarker analysis.

Quanterix Corporation (NASDAQ: QTRX) will announce its financial results for Q4 and full year 2020 after market close on March 2, 2021. Following the announcement, a conference call is scheduled for 4:30 p.m. ET, hosted by CEO Kevin Hrusovsky, to discuss the results and provide a business update. The call will be accessible via phone and a live webcast. Quanterix specializes in digitizing biomarker analysis aimed at advancing precision health.

Quanterix Corporation (NASDAQ: QTRX) will participate in the 10th Annual SVB Leerink Global Healthcare Conference, held virtually from February 22-26, 2021. CEO Kevin Hrusovsky's presentation is scheduled for February 26 at 9:20 a.m. EST. Interested parties can access the live webcast at this link or through the Investor section of Quanterix's website. The webcast will be available for replay for 90 days post-conference. Quanterix focuses on digitizing biomarker analysis to enhance precision health in various therapeutic areas.

Quanterix Corporation (NASDAQ: QTRX) announced a strategic partnership with WuXi AppTec to establish a joint Simoa laboratory in Shanghai, enhancing biomarker testing access across China and the APAC region. This collaboration aims to leverage Quanterix' Simoa HD-X Analyzers and expertise to bolster pre-clinical and clinical research. Starting in 2021, researchers will gain access to Quanterix’ high-definition biomarker technology, which has previously supported over 800 projects. This initiative underscores the importance of biomarkers in advancing disease research and drug development.

Quanterix Corporation (Nasdaq: QTRX) has successfully completed its public offering of 4,107,142 shares at $70.00 each, securing gross proceeds of approximately $287.5 million. This includes an additional 535,714 shares from the underwriters' full exercise of their option. The offering was conducted under a previously filed shelf registration statement with the SEC. Goldman Sachs & Co. LLC, SVB Leerink LLC, and Cowen and Company, LLC were the joint managers, while Canaccord Genuity LLC served as lead manager.

Quanterix Corporation (Nasdaq: QTRX) has announced the pricing of its public offering of 3,571,428 shares of common stock at $70.00 per share, aiming for gross proceeds of approximately $250 million. The offering, which is expected to close on or about February 8, 2021, includes an option for underwriters to purchase an additional 535,714 shares. The offering is filed under a previously effective shelf registration statement. Goldman Sachs, SVB Leerink, and Cowen are the joint bookrunning managers for this offering.

Quanterix Corporation (Nasdaq: QTRX) has launched an underwritten public offering of $200 million of its common stock, with an option for underwriters to purchase an additional 15%. This offering is aimed at supporting its digitization of biomarker analysis, playing a significant role in precision health. The offering will occur under an existing shelf registration statement. Quanterix is working with Goldman Sachs, SVB Leerink, and Cowen as bookrunning managers. Market conditions may affect the completion and final terms of the offering.

Quanterix Corporation (NASDAQ: QTRX) announced that CEO Kevin Hrusovsky will present at the PMWC 2021 COVID-19 Conference from Jan. 25-27, 2021. Hrusovsky will join a panel discussing COVID-19 tracking methodologies on Jan. 25 at 9:50 a.m. PST. Quanterix is advancing precision health through its digital health solution, Simoa, which enhances early disease detection and treatment methods across various therapeutic areas, including oncology and neurology. Founded in 2007, the company is based in Billerica, Massachusetts.

Quanterix (NASDAQ: QTRX) has disclosed operational and preliminary financial results for Q4 and FY 2020. The company thrived despite pandemic challenges, pivoting to develop COVID-19 testing solutions, including an $18.2M NIH contract. Key operational milestones include FDA Emergency Use Authorizations for its antigen tests and significant advancements in neurology biomarkers. Q4 GAAP revenue is projected at $24-26 million, with non-GAAP revenue expected to rise by 32%, totaling $20-22 million. The company raised $97.6 million through a follow-on offering, enhancing its financial position for future growth.